Literature DB >> 23105548

Standardization of a dilution method for cyclosporin (C2) estimation in renal transplant patients.

G Kusumanjali1, Chinnapu G Reddy, A S Kanagasabapathy, Pragna Rao.   

Abstract

Accurate monitoring of blood cyclosporin C2 levels is vital to prevent over immunosuppression and acute renal toxicity in patients who receive organ transplant. The matrix used to dilute patients' C2 samples prior to the assay affected the final measured values. Hence there was a need to develop a method of dilution that would accurately estimate C2 levels when cyclosporin levels were beyond the calibration range of the method employed. Whole blood, cyclosporin free hemolysate and cell and protein free supernatant obtained after pretreatment of normal blood were used to dilute patients' C2 samples. C2 was measured in 188 patients using the supernatant method of dilution. C2 was correlated with Co and dose of cyclosporin received by the patient. The use of cell and protein free supernatant obtained after pretreatment of normal blood as a C2 diluent detected higher levels of C2 in the sample. Measured C2 correlated significantly with Co and the cyclosporin dose received by the patient. The uniformly aqueous cell and protein free supernatant ensures uniform dilution of the patients' C2 sample and measures higher cyclosporin levels.

Entities:  

Keywords:  Cyclosporin; Dilution method; Renal transplant

Year:  2005        PMID: 23105548      PMCID: PMC3453849          DOI: 10.1007/BF02867415

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  4 in total

1.  New approaches to cyclosporine monitoring raise further concerns about analytical techniques.

Authors:  D W Holt; A Johnston; B D Kahan; R G Morris; M Oellerich; L M Shaw
Journal:  Clin Chem       Date:  2000-06       Impact factor: 8.327

Review 2.  Rational clinical regimens for kidney transplant immunosuppression.

Authors:  P Belitsky
Journal:  Transplant Proc       Date:  1994-10       Impact factor: 1.066

3.  Long-term efficacy and safety of cyclosporine in renal-transplant recipients.

Authors:  J F Burke; J D Pirsch; E L Ramos; D R Salomon; D M Stablein; D H Van Buren; J C West
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

4.  Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC.

Authors:  E Schütz; D Svinarov; M Shipkova; P D Niedmann; V W Armstrong; E Wieland; M Oellerich
Journal:  Clin Chem       Date:  1998-10       Impact factor: 8.327

  4 in total
  1 in total

1.  Serum alpha-2-macroglobulin, antitrypsin and antichymotrypsin activities in patients receiving treatment with cyclosporine.

Authors:  Maya Roche; G Kusumanjali; G Chinnapu Reddy; A S Kanagasabhapathy; Pragna Rao
Journal:  Indian J Clin Biochem       Date:  2006-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.